Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Capricor shares soar as potential FDA lifeline revives Duchenne drug hopes

14 August 2026 · By · Wire by Fusion42

Published

14 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at kfgo.com →

◆ Verified

Fusion42 · 15 August 2026 · Fusion42 review

Capricor Therapeutics shares rose 70% after the FDA agreed to review new 24-month data focused on upper limb muscle function for its Duchenne muscular dystrophy drug, deramiocel, pushing back the decision deadline.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 14 Aug 2026 and 25 Aug 2026.

◆ ◆ The Wire takeaway

You have a clearer path to market if you develop Duchenne treatments because FDA review delays can now work in your favour through additional data submissions. This FDA approach means quicker pivots in clinical focus may unlock approvals you should prioritise now.

◆ Coverage

7 sources · first reported 14 Aug 2026 · latest 25 Aug 2026

◆ Topics

BiotechFDA-reviewDuchenne-muscular-dystrophydrug-approvalbiotechclinical-data